# Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT02690701** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 91 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Secukinumab 300 mg
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02690701
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-10
- **Primary completion:** 2017-04-26
- **Final completion:** 2018-02-19
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02690701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02690701, "Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02690701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*